These patients should have a close follow-up in order to decrease complications related to cardiovascular consequences such as atherosclerosis and coronary artery disease [3]. Medical management with HMG-CoA reductase inhibitors has been reported to potentially reduce the size of xanthomatous lesions [7]. The gene discussed is HMGCR; the disease is atherosclerosis.